Philip Rowlands, PhD
Home
About Us
Structure
Current Events
Past Events
Policy & Reports
Awards
Membership
Media Coverage
Internship/Volunteers
Legal
Contact Us
 
 
Philip Rowlands, PhD
Head of the Oncology Therapeutic Area Unit
Takeda Pharmaceuticals

Philip Rowlands, PhD is Head of the Oncology Therapeutic Area Unit (OTAU). In this role, he has overall responsibility for oncology R&D strategy, development portfolio goals and budget. The TAU consists of clinical, program leadership, and program and portfolio management functions, and has matrix leadership responsibility for all development programs from candidate selection through lifecycle management, via cross-functional program teams.

Phil has spent his entire working career in the pharmaceuticals business starting in 1988 in developmental toxicology roles first at Zeneca/ICI and then at Sterling Drug in the UK. Through a series of roles of increasing responsibility in preclinical development, based in the UK, Europe, and then the US, he worked at Sterling, Sanofi, GD Searle and Pharmacia. In 2003, he transferred to Pfizer as an exploratory development director and has been focused exclusively on oncology drug development from that time. He spent eight years at Pfizer leading programs spanning early and late development, before moving to Takeda/Millennium in 2011.

Phil pursued his undergraduate training in pharmacology and toxicology in the UK, and went on to complete his doctoral thesis in mammalian embryology at the University of Leicester Medical School under Professor Felix Beck. He has been resident in the US since 1996 and is based with Takeda in Cambridge, Massachusetts.

© 2007 - USA India Chamber of Commerce Home | About us | Agenda | Council | Policy | Events | Photo Gallery | Awards | Membership | Membership Form | Internship/Volunteers | Legal | Contact us